Investigation summary: the customer issued a complaint for dosing incomplete from pen detected during use of the product by the end-user.One (1) sample was provided to bd medical ¿ pharmaceutical system (bdm-ps) for analysis.Bdm-ps performed a batch history record¿s review (bhr) including a review of all data collected during in process and quality inspections.The batch involved in this complaint meets all acceptable quality levels (aql¿s), was manufactured and released according to applicable procedures and specifications.Initial evaluation revealed no visible damage to the pen.The pen was tested for volumetric dose accuracy per it1172.All doses were within specification, and the pen functioned as intended.An injection sequence was executed using a 29g x 12.7mm bd pen needle and cartridge.Investigation conclusion: based on investigation conclusion, bdm-ps was not able to confirm the symptom perceived by customer or correlate this symptom with a potential cause linked to bd process.Root cause description: based on investigation conclusion, bdm-ps was not able to confirm the symptom perceived by customer or correlate this symptom with a potential cause linked to bd process.Rationale: unconfirmed, no issue observed.Oem manufacture: the manufacturing location for this product is (b)(4).This site is an oem manufacturing site.
|
It was reported that two pen ii mylan 3.0ml experienced an inability to deliver medication during use.The customer reported, "apokyn pen issues: pen doesn't administer medication completely and has to be readministered.This has happened with two pens, request for pen replacement prescription through the hub and md office.She stated this is not the first time this has happened and that sometimes the pens become defective after 2-3 months, and other times after one dose.The current defective pen she has is about 1 week old.".
|